Premium
Disparities in cystic fibrosis survival in Mexico: Impact of socioeconomic status
Author(s) -
Bustamante Adriana E.,
Fernández Lucía T.,
Rivas Lissette C.,
MercadoLongoria Roberto
Publication year - 2021
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.25351
Subject(s) - medicine , hazard ratio , proportional hazards model , socioeconomic status , confidence interval , population , cohort , survival analysis , demography , retrospective cohort study , cohort study , environmental health , sociology
Background Median survival age in cystic fibrosis (CF) has increased in developed countries. Scarce literature exists about survival in Latin America, especially in Mexico. The aim of our study was to assess the median age of survival in CF patients and the impact of risk factors in Mexico over a 20‐year period. Methods We conducted a retrospective study with all patients registered and followed in the CF Center in Monterrey, Mexico from 2000 to 2020. Median survival age was the primary outcome, assessed with Kaplan–Meier analysis. The influence of clinical, biological, and demographic factors on survival was analyzed with Cox regression model. Results Two‐hundred five patients were included. Median survival for the cohort was 21.37 years (95% confidence interval [CI], 17.20–25.55). In the multivariate Cox regression model, low socioeconomic status (hazard ratio [HR], 4.21; 95% CI, 2.43–7.27), chronic Pseudomonas aeruginosa infection at 6 years (HR, 10.45; 95% CI, 5.66–19.28), and pancreatic insufficiency (HR, 3.13; 1.38–7.13) were independent risk factors for mortality. Conclusion Median survival in Mexican patients with CF is lower than in high‐income countries, and socioeconomic status plays a conspicuous role in the disparity. To increase patient survival for those residing in low‐middle income countries, public health authorities must design policies that fully cover diagnosis and treatment strategies for the CF population.